Long-term outcomes of COVID-19 infection in patients with solid tumors


Creative Commons License

Ünsal O., YAZICI O., özkan ö. f., tahtaci g., Ozdemir N., Üner A., ...Daha Fazla

The European Research Journal, cilt.9, sa.5, ss.932-939, 2023 (Hakemli Dergi) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 9 Sayı: 5
  • Basım Tarihi: 2023
  • Doi Numarası: 10.18621/eurj.1251443
  • Dergi Adı: The European Research Journal
  • Derginin Tarandığı İndeksler: Academic Search Premier, EMBASE, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.932-939
  • Gazi Üniversitesi Adresli: Evet

Özet

Objectives: We analyzed the impact of some clinical and disease-specific factors on the longterm outcomes of SARS-CoV-2 infection in patients with solid tumors. Methods: Total of 739 patients with known solid malignancy and infected by SARS-CoV-2 before the beginning of vaccination were examined. Results: Seventy-six cancer patients died from COVID-19 infection-related effects such as mostly pulmonary and cardiovascular system disorders after a median 16-month follow-up (67.1% and 14.5%; respectively). Compared with survivors (n = 468), non-survivors due to COVID-19 infection related effects (n = 76) were more likely to be aged ≥ 65 years and diagnosis with lung cancer (p = 0.01). Also, female patients were at decreased risk of mortality [OR: 0.34 (95% CI: 0.18-0.65)]. Furthermore, patients with tumor stage IV, active/stable/progressive disease and patients receiving active anticancer therapy were at increased risk of mortality (p = 0.01). Conclusions: The patients with aged ≥ 65 years, diagnosed with lung cancer, receiving active anticancer therapy, with active/stable/progressive and advanced cancer stage were at increased risk of mortality from COVID-19 infection in long-term follow-up.